U.S. Markets closed

[$$] Patients Win With More Access to Treatments

The Food and Drug Administration’s approval of Sarepta Therapeutic’s Duchenne drug is a teachable moment for 21st-century regulatory science (“A Risky Drug Approval Lesson”, Review and Outlook, July 5). The FDA cannot regulate drug trials properly without factoring in patients’ opinions. Is that calculation reproducible across therapeutic categories? istock/getty images View of human skeletal muscle under a microscope.